STAT+: Drug makers sue HHS over a discount program serving low-income populations
In a clutch of lawsuits, three drug makers argue the federal government is wrong to insist they must provide discounts on medicines to pharmacies that work with hospitals and clinics that serve primarily low-income populations.
The claims made by AstraZeneca (AZN), Sanofi, (SNY), and Eli Lilly (LLY) follow a recent advisory opinion issued by the Department of Health and Human Services, which maintained drug companies were wrong to curtail price breaks required as part of the 340B drug discount program.
Continue to STAT+ to read the full story…
